Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffry P Simko

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
The American Journal of Surgical Pathology|May 28, 2020
The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic CarcinomaGeert J L H van Leenders, Theodorus H van der Kwast, David J Grignon, et al.
JCO Precision Oncology|October 24, 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital HistopathologyJonathan David Tward, Huei-Chung Huang, Andre Esteva, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized TrialsPaul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2022
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521William A Hall, Theodore G Karrison, Seth A Rosenthal, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 TrialDaniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005Kristin A Higgins, Chen Hu, Helen J Ross, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 11, 2022
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinomaEmily Chan, Jesse K McKenney, Sarah Hawley, et al.
JCO Clinical Cancer Informatics|May 9, 2025
Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III TrialsMack Roach, Jingbin Zhang, Osama Mohamad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2025
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III TrialsAndrew J Armstrong, Vinnie Y T Liu, Ramprasaath R Selvaraju, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
The American Journal of Surgical Pathology|May 28, 2020
The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic CarcinomaGeert J L H van Leenders, Theodorus H van der Kwast, David J Grignon, et al.
JCO Precision Oncology|October 24, 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital HistopathologyJonathan David Tward, Huei-Chung Huang, Andre Esteva, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized TrialsPaul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2022
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521William A Hall, Theodore G Karrison, Seth A Rosenthal, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 TrialDaniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005Kristin A Higgins, Chen Hu, Helen J Ross, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 11, 2022
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinomaEmily Chan, Jesse K McKenney, Sarah Hawley, et al.
JCO Clinical Cancer Informatics|May 9, 2025
Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III TrialsMack Roach, Jingbin Zhang, Osama Mohamad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2025
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III TrialsAndrew J Armstrong, Vinnie Y T Liu, Ramprasaath R Selvaraju, et al.
Pageof 10